Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report.
Darice Y WongBrent L FogelPublished in: Journal of medical case reports (2021)
The metabolism of ondansetron, metoclopramide, or prochlorperazine in patients with the *41 CYP2D6 allele has not been studied. In this family, clinical evidence implicates the *41 CYP2D6 allele as causing extrapyramidal adverse pharmacologic reactions. Patients with a family history of medication-induced dystonia involving these medications should be considered for pharmacogenomic testing, and patients carrying the *41 CYP2D6 allele should consider reduction or avoidance of CYP2D6-mediated medications to minimize the potential risk of adverse extrapyramidal effects.
Keyphrases
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- healthcare
- adverse drug
- drug induced
- liver failure
- early onset
- peritoneal dialysis
- oxidative stress
- intensive care unit
- deep brain stimulation
- acute respiratory distress syndrome
- climate change
- endothelial cells
- extracorporeal membrane oxygenation